Unknown

Dataset Information

0

PAX8 lineage-driven T cell engaging antibody for the treatment of high-grade serous ovarian cancer.


ABSTRACT: High-grade serous ovarian cancers (HGSOC) represent the most common subtype of ovarian malignancies. Due to the frequency of late-stage diagnosis and high rates of recurrence following standard of care treatments, novel therapies are needed to promote durable responses. We investigated the anti-tumor activity of CD3 T cell engaging bispecific antibodies (TCBs) directed against the PAX8 lineage-driven HGSOC tumor antigen LYPD1 and demonstrated that anti-LYPD1 TCBs induce T cell activation and promote in vivo tumor growth inhibition in LYPD1-expressing HGSOC. To selectively target LYPD1-expressing tumor cells with high expression while sparing cells with low expression, we coupled bivalent low-affinity anti-LYPD1 antigen-binding fragments (Fabs) with the anti-CD3 scFv. In contrast to the monovalent anti-LYPD1 high-affinity TCB (VHP354), the bivalent low-affinity anti-LYPD1 TCB (QZC131) demonstrated antigen density-dependent selectivity and showed tolerability in cynomolgus monkeys at the maximum dose tested of 3 mg/kg. Collectively, these data demonstrate that bivalent TCBs directed against LYPD1 have compelling efficacy and safety profiles to support its use as a treatment for high-grade serous ovarian cancers.

SUBMITTER: Lee E 

PROVIDER: S-EPMC8295318 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC5173106 | biostudies-literature
| S-EPMC9816987 | biostudies-literature
| S-EPMC6865034 | biostudies-literature
2016-08-08 | E-GEOD-83101 | biostudies-arrayexpress
2016-08-08 | GSE83101 | GEO
2016-08-08 | E-GEOD-79893 | biostudies-arrayexpress
2016-08-08 | E-GEOD-83100 | biostudies-arrayexpress
2016-08-08 | GSE83100 | GEO
2016-08-08 | GSE79893 | GEO
2016-09-23 | GSE79572 | GEO